The development of molecular breast cancer therapies in the past few decades has considerably improved treatment of the disease. This Review chronicles these advances and discusses future treatment targets, namely steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (in estrogen-dependent breast cancers), and treatment strategies, including combinatory therapies and the use of techniques such as RNA silencing and functional genomics.
- Sheng-Xiang Lin
- Jiong Chen
- Ming Zhou